Crossmark

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

Crossref DOI link: https://doi.org/10.1038/s41392-021-00751-9

Published Online: 2021-10-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiang, Tao https://orcid.org/0000-0002-9205-8183
Wang, Pingyang

Zhang, Jie

Zhao, Yanqiu

Zhou, Jianying

Fan, Yun

Shu, Yongqian

Liu, Xiaoqing

Zhang, Helong

He, Jianxing

Gao, Guanghui

Mu, Xiaoqian

Bao, Zhang

Xu, Yanjun

Guo, Renhua

Wang, Hong

Deng, Lin

Ma, Ningqiang

Zhang, Yalei

Feng, Hui

Yao, Sheng

Wu, Jiarui

Chen, Luonan

Zhou, Caicun https://orcid.org/0000-0002-1072-9941
Ren, Shengxiang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81871865, 81972167)
License Information

Text and Data Mining valid from 2021-10-15

Version of Record valid from 2021-10-15
More Information

Article History

Received: 5 May 2021

Revised: 24 August 2021

Accepted: 25 August 2021

First Online: 15 October 2021

Competing interests

: Honoraria to Dr. Caicun Zhou: Lilly, Roche, Boehringer Ingelheim, MSD, Hengrui Therapeutics, and QiLu Pharmaceutical; Consulting or advisory role: AmoyDx, Hengrui Therapeutics, Inovent, and QiLu Pharmaceutical. Other authors declared no potential conflicts of interest.

Document is current

Any future updates will be listed below